Cogent Biosciences, Inc. (COGT) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
COGT Revenue Growth
Revenue Breakdown (FY 2019)
COGT's revenue distribution by segment and geography for fiscal year 2019
By Product/Segment
COGT Revenue Analysis (2015–2025)
As of May 8, 2026, Cogent Biosciences, Inc. (COGT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, COGT's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $22.5 million in 2019.
Revenue diversification analysis shows COGT's business is primarily driven by Preclinical Research And Clinical Development (100%). With over half of revenue concentrated in Preclinical Research And Clinical Development, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), MRUS (+55.9% YoY), and ALGS (-42.7% YoY). Compare COGT vs KYMR →
COGT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| COGTCurrent | $0 | - | - | - | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 MRUS | $35M | +55.9% | +4.7% | -753.0% | |
 ALGS | $2M | -42.7% | - | -4024.9% |
COGT Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-4,619,000 | - | $-333,363,000 | - |
| 2024 | $0 | - | $0 | - | $-275,939,000 | - |
| 2023 | $0 | - | $0 | - | $-208,130,000 | - |
| 2022 | $0 | - | $0 | - | $-147,839,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-75,551,000 | - |
| 2020 | $7.9M | -65.0% | $-17,867,000 | -227.0% | $-82,199,000 | -1044.3% |
| 2019 | $22.5M | +131.1% | $22.5M | 99.8% | $-32,178,000 | -143.0% |
| 2018 | $9.7M | +16.4% | $9.7M | 100.0% | $-36,005,000 | -369.9% |
| 2017 | $8.4M | +31.6% | $8.4M | 100.0% | $-26,152,000 | -312.8% |
| 2016 | $6.4M | +112.8% | $6.4M | 100.0% | $-19,070,000 | -300.1% |
See COGT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COGT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COGT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCOGT — Frequently Asked Questions
Quick answers to the most common questions about buying COGT stock.
Is COGT's revenue growth accelerating or slowing?
COGT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is COGT's long-term revenue growth rate?
Cogent Biosciences, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is COGT's revenue distributed by segment?
COGT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.